Indegene Ltd (NSE: INDGN, BSE: 544172) is a Bengaluru, Karnataka-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹14,413 Cr, it ranks #477 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 10 in Life Sciences Tools and Services. At ₹571.90 (as of 25 Oct 2026), the share price is 8.8% below its 52-week high of ₹627.00 and 38.1% above its 52-week low of ₹414.00. The share price is up 5.9% over one year and up 16.1% over three months.
| Current Price | ₹571.90 |
|---|---|
| Market Cap | ₹14,413 Cr |
| NSE Symbol | INDGN |
| BSE Code | 544172 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 35.2 |
| Return on Equity | 13.94% |
| Return on Assets | 7.82% |
| 52-Week Range | ₹414.00 – ₹627.00 |
| 1-Year Price Change | +5.9% |
| 3-Month Price Change | +16.1% |
| Beta (1Y) | 0.42 |
| Dividend Yield | 0.38% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.indegene.com |
| Revenue | ₹1,063 Cr |
|---|---|
| Net Profit | ₹116 Cr |
| Net Margin | 10.9% |
| EPS (Basic) | ₹4.84 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
1. Enterprise Medical Solutions-This segment offers enterprise medical solutions, including creation and review of medical content, medical communication review, pharmacovigilance, and other safety services, as well as labelling, regulatory submissions, and pricing and market access services. 2. Enterprise Commercial Solutions-This segment develops, deploys, and measures sales and marketing activities, including generation of marketing and promotional content. 3. Others-NA 4. Segment Adjustment-NA
1. Enterprise Medical Solutions-26.5% 2. Others-3.4% 3. Enterprise Commercial Solutions (Incl. Omnichannel Activation)-70.1%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,413 Cr | 35.2 | 13.94% | ₹1,063 Cr | +5.9% |
| Suven Life Sciences Ltd. | ₹8,583 Cr | -24 | -78.80% | ₹4 Cr | +30.6% |
| Vimta Labs Ltd | ₹2,338 Cr | 29.3 | 18.55% | ₹109 Cr | -32.5% |
| Tarsons Products Limited | ₹1,762 Cr | 117.2 | 2.26% | ₹110 Cr | +3.3% |
| Bilcare Ltd. | ₹224 Cr | 122.4 | -5.21% | — | — |
| Brooks Laboratories Ltd. | ₹199 Cr | 8.1 | 22.28% | ₹23 Cr | -53.0% |
| Jeevan Scientific Technology Ltd | ₹178 Cr | 130.4 | 1.68% | — | +34.0% |
| Vivo Bio Tech Ltd. | ₹31 Cr | -16.6 | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹28 Cr | -2.8 | -68.79% | — | -32.7% |
Listed by market capitalisation. Ratios are shown for context only.
Indegene Ltd is trading at ₹571.90, with a market capitalisation of ₹14,413 Cr.
Indegene Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Indegene Ltd has a P/E of 35.2 and a return on equity of 13.94%.
Indegene Ltd is listed on the NSE under the symbol INDGN and on the BSE under the scrip code 544172.
Indegene Ltd's share price is up 5.9% over one year and up 16.1% over three months. Its 52-week range is ₹414.00 to ₹627.00.
In Q1 FY27, Indegene Ltd reported revenue of ₹1,063 Cr and net profit of ₹116 Cr, with basic EPS of ₹4.84 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.